Depression News and Research

Latest Depression News and Research

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

8 Sep 2010

Interventions targeting social cognition most effective in mitigating loneliness

Changing how a person perceives and thinks about others was the most effective intervention for loneliness, a sweeping analysis of previous research has determined. The findings may help physicians and psychologists develop better treatments for loneliness, a known risk factor for heart disease and other health problems.

8 Sep 2010

AHRQ releases free evidence-based guides for eight health conditions

HHS' Agency for Healthcare Research and Quality today released a series of free evidence-based guides designed to help Spanish speakers understand and compare the risks, benefits and side effects of treatments for eight health conditions.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Study reveals high rate of parental depression in first year after child's birth

More than one-third of mothers and about one-fifth of fathers in the United Kingdom appear to experience an episode of depression between their child's birth and 12th year of age, with the highest rates in the first year after birth, according to a report posted online today that will appear in the November print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online today in the Archives of General Psychiatry.

7 Sep 2010

TNS therapy improves depression: Study

Major depression is a common and disabling brain condition marked not only by the presence of depressed mood but also by its effects on sleep, energy, decision-making, memory and thoughts of death or of suicide.

3 Sep 2010

More support needed for erectile dysfunction says sexologist

According to sexologist Bettina Arndt, there are thousands of Australian men with erectile dysfunction who are sexually impotent because of their condition and the lack of affordable treatments. Arndt said that funds distribution for breast prostheses for female cancer patients is one of the examples of mismatches in funding.

3 Sep 2010

Dilemmas created for healthcare professionals by medicinal use of cannabis

Nurses have a responsibility to respect and support patients who use cannabis for medicinal purposes, but must stay within the law and follow professional guidance at all times, according to a research review in the September issue of the Journal of Clinical Nursing.

3 Sep 2010

PCOS Challenge creates television series to help women with Polycystic Ovarian Syndrome

In an effort to bring greater awareness to Polycystic Ovarian Syndrome, PCOS Challenge, Inc. has created a 13-week television series to help women with PCOS. PCOS is estimated to affect one-in-ten women of childbearing age. It can lead to other serious conditions including endometrial cancer, obesity, diabetes and infertility.

3 Sep 2010

BAP releases new guidelines on treatments for sleep disorders

Insomnia and other sleep disorders are very common, yet are not generally well understood by doctors and other health care professionals. Now the British Association for Psychopharmacology (BAP) has released up-to-the-minute guidelines in the Journal of Psychopharmacology, published by SAGE, to guide psychiatrists and physicians caring for those with sleep problems.

3 Sep 2010

Study reveals factors linked to cognitive impairment in Type 2 diabetes

Older adults with diabetes who have high blood pressure, walk slowly or lose their balance, or believe they're in bad health, are significantly more likely to have weaker memory and slower, more rigid cognitive processing than those without these problems, according to a new study published by the American Psychological Association.

3 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Lack of sleep linked to depression and anxiety disorders in young

According to Australian research, youngsters getting inadequate sleep are at risk of mental ailments. Researcher Nicholas Glozier of the University of Sydney said, the increase in incidence of mental ailments in the young has been puzzling health experts. The answer may lie in inadequate sleep.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

Evotec AG announces Closing conditions to acquire DeveloGen

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

2 Sep 2010

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

A study in the Sept. 1 issue of the journal SLEEP found an elevated risk of death in men with a complaint of chronic insomnia and an objectively measured short sleep duration. The results suggest that public health policy should emphasize the diagnosis and appropriate treatment of chronic insomnia.

2 Sep 2010

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Anxiety disorders afflict women twice as often as men, but estrogen might not be the reason. Testosterone, though, could be. That is one of the preliminary findings in the lab of Florida State University researcher Mohamed Kabbaj, associate professor in the College of Medicine. He recently was awarded a five-year, $1.8 million grant from the National Institute of Mental Health to investigate the sex differences in anxiety.

2 Sep 2010

Depression News and Research

Latest Depression News and Research

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

Interventions targeting social cognition most effective in mitigating loneliness

AHRQ releases free evidence-based guides for eight health conditions

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Somaxon's Silenor now commercially available in U.S.

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Study reveals high rate of parental depression in first year after child's birth

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

TNS therapy improves depression: Study

More support needed for erectile dysfunction says sexologist

Dilemmas created for healthcare professionals by medicinal use of cannabis

PCOS Challenge creates television series to help women with Polycystic Ovarian Syndrome

BAP releases new guidelines on treatments for sleep disorders

Study reveals factors linked to cognitive impairment in Type 2 diabetes

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Lack of sleep linked to depression and anxiety disorders in young

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Evotec AG announces Closing conditions to acquire DeveloGen

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

Researcher awarded $1.8M grant to investigate sex differences in anxiety

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Depression News and Research

Latest Depression News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in